IBB

Crude oil near $98 pushed the 10‑year Treasury yield above 4.8%, the highest since 2023, and the Dow fell as traders priced a Fed rate hike next week. The S&P 500 and Nasdaq also slipped in response to the inflation worries.

Biotech stocks outperformed the S&P 500 by 22 points over three months, marking one of the sector’s sharpest reversals in years. Investors now face the question of whether the momentum still exists or if the easy money has already exited.

My clustering stock screener is giving us a much more interesting macro signal than simply energy stocks are strong. The portfolio is not simply long commodities. It's long capital intensity

GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real value of mRNA technology sits right now.

Novavax shares rose 6% after speculation that its Matrix‑M oncology vaccine could change the company’s royalty model. The actual business model shift happened quietly last week and is unrelated to oncology.

Oil prices climbed above $88 and the 10‑year Treasury yield hit a 19‑month high, raising Fed rate‑hike odds to 68%. The rise in yields contributed to a pullback in high‑multiple software stocks.

Moderna’s cancer vaccine breakthrough has put biotech, mRNA, and genomics ETFs in focus. The article highlights specific funds that may benefit from this potential biotech boom.

The article references a Smart Beta ETF report for IBB.